Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/14295
Título
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
Autor(es)
Berenguer, Juan | Díez, Cristina | Martin-Vicente, Maria ISCIII | Mican, Rafael | Pérez-Elías, María J | García-Fraile, Lucio J | Vidal, Francisco | Suárez-García, Inés | Podzamczer, Daniel | Del Romero, Jorge | Pulido, Federico | Iribarren, José A | Gutiérrez, Félix | Poveda, Eva | Galera, Carlos | Izquierdo Miguel, Rebeca ISCIII | Asensi, Víctor | Portilla, Joaquín | López, Juan C | Arribas, José R | Moreno, Santiago | González-García, Juan | Resino, Salvador ISCIII | Jarrin-Vera, Inmaculada ISCIII
Fecha de publicación
2021-11
Cita
Clin Microbiol Infect. 2021 Nov;27(11):1678-1684.
Idioma
Inglés
Tipo de documento
research article
Resumen
Objectives: We aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and factors associated with seropositivity and asymptomatic coronavirus disease 2019 (COVID-19) among people with HIV (PWH). Methods: This was a cross-sectional study carried out within the cohort of the Spanish HIV Research Network. Participants were consecutive PWH with plasma collected from 1st April to 30th September 2020. We determined SARS-CoV-2 antibodies (Abs) in plasma. Illness severity (NIH criteria) was assessed by a review of medical records and, if needed, participant interviews. Multivariable logistic regression analysis was used to identify predictors of seropositivity among the following variables: sex, age, country of birth, education level, comorbidities (hypertension, chronic heart disease, diabetes mellitus, non AIDS-related cancer, chronic kidney disease, cirrhosis), route of HIV acquisition, prior AIDS, CD4þ cell count, HIV viral load, nucleoside/nucleotide reverse transcriptase inhibitor (N [t]RTI) backbone, type of third antiretroviral drug, and month of sample collection. Results: Of 1076 PWH (88.0% males, median age 43 years, 97.7% on antiretroviral therapy, median CD4þ 688 cells/mm3 , 91.4% undetectable HIV viral load), SARS-CoV-2 Abs were detected in 91 PWH, a sero prevalence of 8.5% (95%CI 6.9e10.3%). Forty-five infections (45.0%) were asymptomatic. Variables inde pendently associated with SARS-CoV-2 seropositivity were birth in Latin American countries versus Spain (adjusted odds ratio (aOR) 2.30, 95%CI 1.41e3.76, p 0.001), and therapy with tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) versus tenofovir alafenamide (TAF)/FTC as the N(t)RTI backbone (aOR 0.49, 95%CI 0.26e0.94, p 0.031). Conclusions: Many SARS-CoV-2 infections among PWH were asymptomatic, and birth in Latin American countries increased the risk of SARS-CoV-2 seropositivity. Our analysis, adjusted by comorbidities and other variables, suggests that TDF/FTC may prevent SARS-CoV-2 infection among PWH.
Palabras clave
Versión en línea
DOI
Aparece en las colecciones
- Investigación > IIS > IIS BioGipuzkoa - Asociación Instituto de Investigación Sanitaria BioGipuzkoa (País Vasco)
- Investigación > ISCIII > Centro Nacional de Epidemiología (CNE)
- Investigación > ISCIII > Centro Nacional de Microbiología (CNM)
- Investigación > IIS > i+12 - Instituto de Investigación Hospital 12 de Octubre (Madrid)
- Investigación > IIS > IdiPAZ - Instituto de Investigación Sanitaria Hospital La Paz (Madrid)
- Investigación > IIS > IiSGM - Instituto de Investigación Sanitaria Gregorio Marañón (Madrid)
- Investigación > IIS > IISGS - Instituto de Investigación Sanitaria Galicia Sur (Galicia)
- Investigación > IIS > IRYCIS - Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)
Ficheros en el ítem
![Acceso Abierto Acceso Abierto](/themes/Mirage2/images/openAccess.png)
- Nombre:
- PrevalenceAndFactorsAssociated ...
- Tamaño:
- 433.7Kb
- Formato:
- Descripción:
- Artículo principal